About Alimera Sciences
Alimera Sciences is a Healthcare company based in Alpharetta (United States) founded in 2003, and was acquired by ANI Pharmaceuticals in July 2024. Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. It operates on a Reseller / Distribution model. Alimera Sciences has raised $66.8 million across 9 funding rounds from investors including ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital. The company has 79 employees. Alimera Sciences offers products and services including Ophthalmic Products. Its focus areas include Pharmaceuticals and Ophthalmic Drugs. Its legal entity is Alimera Sciences Europe Ltd. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Alimera Sciences is involved in the distribution of ophthalmic pharmaceutical products across Europe, the Middle East, and Africa. The company collaborates with a network of distribution partners to provide solutions for eye-related conditions. Operations are focused on ensuring access to specialized treatments in various countries within these regions.
- Headquarters Alpharetta, United States
- Employees 79
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website alimerasciences.com
- Social LinkedIn X Facebook
- Acquired by ANI Pharmaceuticals (Jul 2024)
- Legal Name Alimera Sciences Europe Ltd
- Annual Revenue$80.75 M (USD)49as on Dec 31, 2023
- Net Profit-$20.13 M (USD)-11as on Dec 31, 2023
- EBITDA$6.82 M (USD)176as on Dec 31, 2023
- Total Equity Funding$66.8M (USD)
in 9 rounds
- Latest Funding Round$81M (USD), Post-IPO
May 2023
- InvestorsANI Pharmaceuticals
& 7 more
- Employee Count79
- Acquired byANI Pharmaceuticals
(Jul 2024)
Products & Services of Alimera Sciences
Alimera Sciences offers a comprehensive portfolio of products and services, including Ophthalmic Products.
Products for eye conditions are developed and distributed.
Funding Insights of Alimera Sciences
Alimera Sciences has successfully raised a total of $66.8M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $81 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $66.8M
- Total Rounds 9
- Last Round Post-IPO — $81M
- First Round $31.8M
(Nov 2005)
- Investors Count 7
All 9 funding rounds of Alimera Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $81M | Post-IPO | – | – | – |
| Oct 2019 | $20M | Post-IPO | – | – | |
| Jan 2018 | $40M | Debt – Conventional | – | – | |
| Feb 2014 | $37.5M | Post-IPO | – | – | – |
| Oct 2012 | $40M | Post-IPO | – | – | – |
| May 2011 | $332,486 | Post-IPO | – | – | – |
| Sep 2009 | $5M | Series C | – | Polaris Partners, Intersouth Partners | – |
| Mar 2008 | $30M | Series C | – | – | – |
| Nov 2005 | $31.8M | Series B | – | – |
8 investors in total: 8 institutional.
Investors in Alimera Sciences
Alimera Sciences has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include ANI Pharmaceuticals, SLR Investment Corp and Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States | ||
Debt and equity investments are offered by the firm. | 2006 | solarcapltd.com | New York, United States | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Early-stage venture capital investments are focused on US companies. | scalevp.com | Foster City, United States | ||
Branded and generic prescription drugs are developed, manufactured, and marketed. | 1996 | anipharmaceuticals.com | Baudette, United States |
Investor details for Alimera Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alimera Sciences
41 people are tracked at Alimera Sciences (15 in leadership, 26 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
Russell Skibsted | CFO & SVP | Leadership |
Alexandre Benites | Director Of Financial Planning And Analysis | Leadership |
Emma Head | Human Resources Business Partner, Europe | Leadership |
Joan Hester | Senior Director Of Medical Affairs | Leadership |
Riz Siddiqi | Medical Director, UK & Eire | Leadership |
Ben Flagler | Regional Sales Director | Leadership |
Tom Sinnamon | Region Director Of Sales | Leadership |
Brittany Underhill | Associate Director, Financial Reporting | Leadership |
David Dyer | Chief Retina Specialist | Leadership |
Deirdre O Reilly | Associate Director Corporate Compliance Training | Leadership |
David Gregory | Associate Director Of Data, Analytics And Innovation | Leadership |
Beatriz Rumsey P. Torres | Director, Medical Affairs, EMEA | Leadership |
Laura Cegala Sphr, Gphr | Executive Director Human Resources, Sphr, GPHR | Leadership |
Steve Morris | Vice President , Medical Director Uk, Head Of Medical Affairs Europe | Leadership |
Bill Garner | Executive Director Marketing | Leadership |
Janine Ainslie Harris | Global Creative And Communications Lead | Team |
Cheryl O'Keeffe | Field Sales Trainer | Team |
Matthew Ciavirella | Key Account Manager | Team |
Iman Haydar Ahmad | Medical Affairs ME And Product Specialist | Team |
Anastasia Turano | Senior Thought Leader Liaison | Team |
21 more people are available in the full profile.
Complete people profiles for Alimera Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alimera Sciences
5 dated milestones of Alimera Sciences across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Alimera Sciences is founded.
- Funding First funding round of $31.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $81.0M.
- Exit Acquired by ANI Pharmaceuticals.
Competitors of Alimera Sciences
Alimera Sciences has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Alimera Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alimera Sciences
Websites that share an audience with Alimera Sciences (alimerasciences.com).
Websites whose visitors overlap most with Alimera Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| psivida.com | 100% | View details | |||
| anthera.com | 74% | View details | |||
| alexza.com | 71% | View details | |||
| lpath.com | 63% | View details | |||
retinavitreous.com | retinavitreous.com | 49% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Alimera Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Alimera Sciences (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alimera Sciences
Complete news archive for Alimera Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alimera Sciences
Alimera Sciences was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Alimera Sciences is headquartered in Alpharetta, United States. It is registered at Alpharetta, Georgia, United States.
Alimera Sciences is a funded company, having raised a total of $66.8M across 9 funding rounds to date. The company's 1st funding round was a Series B of $31.8M, raised on Nov 2005.
Alimera Sciences has 79 employees.
Annual revenue of Alimera Sciences is $80.75M as on Dec 31, 2023.
Alimera Sciences is involved in the distribution of ophthalmic pharmaceutical products across Europe, the Middle East, and Africa. The company collaborates with a network of distribution partners to provide solutions for eye-related conditions. Operations are focused on ensuring access to specialized treatments in various countries within these regions.
Alimera Sciences's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
Alimera Sciences offers Ophthalmic Products.
Alimera Sciences has 8 investors. Key investors include ANI Pharmaceuticals, SLR Investment Corp, Lincoln Park Capital, Polaris Partners, and Intersouth Partners.
Alimera Sciences operates through Alimera Sciences Europe Ltd.
Yes. Alimera Sciences was acquired by ANI Pharmaceuticals in July 2024.